ImmuneOnco (1541) Redeems Existing Wealth Products and Subscribes to HK$120 Million Product

Bulletin Express11-20

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541) announced that it redeemed its entire holdings in two previously subscribed wealth management products from Huatai Financial on November 20, 2025. The redeemed amounts were HK$49,603,273 and HK$43,720,000, yielding estimated unaudited interest incomes of approximately HK$3,460,000 and HK$1,270,000, respectively. These redemptions concluded the company’s position in any Huatai Financial products.

On the same day, ImmuneOnco entered into a subscription agreement to purchase a new wealth management product from Huatai Financial for HK$120,000,000. The one-year structured note is expected to offer an annualized rate of return ranging from 1.5% to 4.5% and is redeemable with ten business days’ notice. The subscription was funded entirely by the company’s internal surplus cash reserves.

Based on the Listing Rules, the redemptions and new subscription each exceed 5% but are below 25% in the applicable percentage ratios, classifying them as discloseable transactions. Consequently, they are subject to notification and announcement requirements under Chapter 14 of the Listing Rules but are exempt from shareholder approval requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1169998077?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 22:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169998077","market":"hk","top_or_hot":-1,"title":"ImmuneOnco (1541) Redeems Existing Wealth Products and Subscribes to HK$120 Million Product","media":"Bulletin Express","content":"<p>ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541) announced that it redeemed its entire holdings in two previously subscribed wealth management products from Huatai Financial on November 20, 2025. The redeemed amounts were HK$49,603,273 and HK$43,720,000, yielding estimated unaudited interest incomes of approximately HK$3,460,000 and HK$1,270,000, respectively. These redemptions concluded the company’s position in any Huatai Financial products.</p>\n<p>On the same day, ImmuneOnco entered into a subscription agreement to purchase a new wealth management product from Huatai Financial for HK$120,000,000. The one-year structured note is expected to offer an annualized rate of return ranging from 1.5% to 4.5% and is redeemable with ten business days’ notice. The subscription was funded entirely by the company’s internal surplus cash reserves.</p>\n<p>Based on the Listing Rules, the redemptions and new subscription each exceed 5% but are below 25% in the applicable percentage ratios, classifying them as discloseable transactions. Consequently, they are subject to notification and announcement requirements under Chapter 14 of the Listing Rules but are exempt from shareholder approval requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmuneOnco (1541) Redeems Existing Wealth Products and Subscribes to HK$120 Million Product</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuneOnco (1541) Redeems Existing Wealth Products and Subscribes to HK$120 Million Product\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-20 22:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541) announced that it redeemed its entire holdings in two previously subscribed wealth management products from Huatai Financial on November 20, 2025. The redeemed amounts were HK$49,603,273 and HK$43,720,000, yielding estimated unaudited interest incomes of approximately HK$3,460,000 and HK$1,270,000, respectively. These redemptions concluded the company’s position in any Huatai Financial products.</p>\n<p>On the same day, ImmuneOnco entered into a subscription agreement to purchase a new wealth management product from Huatai Financial for HK$120,000,000. The one-year structured note is expected to offer an annualized rate of return ranging from 1.5% to 4.5% and is redeemable with ten business days’ notice. The subscription was funded entirely by the company’s internal surplus cash reserves.</p>\n<p>Based on the Listing Rules, the redemptions and new subscription each exceed 5% but are below 25% in the applicable percentage ratios, classifying them as discloseable transactions. Consequently, they are subject to notification and announcement requirements under Chapter 14 of the Listing Rules but are exempt from shareholder approval requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"","article_id":"1169998077","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169998077","pubTimestamp":1763647344,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541) announced that it redeemed its entire holdings in two previously subscribed wealth management products from Huatai Financial on November 20, 2025....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01541":"宜明昂科-B"},"translate_title":"ImmuneOnco(1541)赎回现有理财产品及认购1.2亿港元产品","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1},"content_text":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541) announced that it redeemed its entire holdings in two previously subscribed wealth management products from Huatai Financial on November 20, 2025. The redeemed amounts were HK$49,603,273 and HK$43,720,000, yielding estimated unaudited interest incomes of approximately HK$3,460,000 and HK$1,270,000, respectively. These redemptions concluded the company’s position in any Huatai Financial products.\nOn the same day, ImmuneOnco entered into a subscription agreement to purchase a new wealth management product from Huatai Financial for HK$120,000,000. The one-year structured note is expected to offer an annualized rate of return ranging from 1.5% to 4.5% and is redeemable with ten business days’ notice. The subscription was funded entirely by the company’s internal surplus cash reserves.\nBased on the Listing Rules, the redemptions and new subscription each exceed 5% but are below 25% in the applicable percentage ratios, classifying them as discloseable transactions. Consequently, they are subject to notification and announcement requirements under Chapter 14 of the Listing Rules but are exempt from shareholder approval requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1169998077","isCrawlerRequest":true}